MODERNA, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 124.3 USD | +1.34% |
|
-3.50% | +21.30% |
| 03:17pm | Sector Update: Health Care Stocks Edge Higher Premarket Friday | MT |
| 02:54pm | Moderna's RSV Vaccine Review Delayed by FDA to End of May | MT |
Presenter SpeechTerence Flynn (Analysts)Great. Well, good afternoon, everybody. Thanks for joi...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
122.7
USD
Average target price
139.4
USD
Spread / Average Target
+13.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +21.30% | 47.02B | |
| +49.62% | 41.86B | |
| +0.57% | 41.76B | |
| -4.27% | 28.8B | |
| +12.37% | 26.05B | |
| -21.41% | 19.15B | |
| +3.84% | 12.55B | |
| +32.40% | 12.34B | |
| -2.65% | 11.82B | |
| +21.36% | 11.8B |
- Stock Market
- Equities
- MRNA Stock
- News Moderna, Inc.
- Transcript : Moderna, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 12